Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial

Catherine S. Diefenbach, Fangxin Hong, Richard F. Ambinder, Jonathon B. Cohen, Michael J. Robertson, Kevin A. David, Ranjana H. Advani, Timothy S. Fenske, Stefan K. Barta, Neil D. Palmisiano, Jakub Svoboda, David S. Morgan, Reem Karmali, Elad Sharon, Howard Streicher, Brad S. Kahl, Stephen M. Ansell

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Fingerprint Dive into the research topics of 'Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences